An evidence-based systematic review of bilberry (Vaccinium myrtillus) by the natural standard research collaboration

Journal of Dietary Supplements

Volumn 6, Issue 2, 2009, Pages 162-200

  Ulbricht, Catherine ^a   Basch, Ethan ^b   Basch, Samuel ^c   Bent, Steve ^d   Boon, Heather ^e   Burke, Dilys ^a   Costa, Dawn ^a   Falkson, Carla ^f   Giese, Nicole ^a   Goble, Michael ^g   Hashmi, Sadaf ^h   Mukarjee, Siddhartta ⁱ   Papaliodis, George ^j   Seamon, Erica ^a   Shaina, Tanguay Colucci ^a   Weissner, Wendy ^a   Woods, Jen ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c MOUNT SINAI MEDICAL CENTER   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF TORONTO   (Canada)

^f UNIVERSITY OF ALABAMA   (United States)

^g Massachusetts College of Pharmacy   (United States)

^h HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

ⁱ HARVARD MEDICAL SCHOOL   (United States)

^j MASSACHUSETTS EYE AND EAR INFIRMARY   (United States)

more..

Author keywords

Adverse effects; Bilberry(Vaccinium myrtillus); Dosing; Evidence based; Interactions; Pharmacodynamics; Pharmacokinetics; Pharmacology; Systematic review

Indexed keywords

ANTHOCYANIN; VACCINIUM MYRTILLUS EXTRACT;

COOPERATION; EVIDENCE BASED MEDICINE; HUMAN; PHYTOTHERAPY; REVIEW; VACCINIUM MYRTILLUS;

ANTHOCYANINS; COOPERATIVE BEHAVIOR; EVIDENCE-BASED MEDICINE; HUMANS; PHYTOTHERAPY; VACCINIUM MYRTILLUS;

VACCINIUM MYRTILLUS;

EID: 67650663732     PISSN: 19390211     EISSN: None     Source Type: Journal    
DOI: 10.1080/19390210902861858     Document Type: Review

References (78)

1. Allen FM. Blueberry leaf extract: physiologic and clinical properties in relation to carbohydrate metabolism. JAMA. 1927;89:1577-1581.
2. Amouretti M. Therapeutic value of Vaccinium myrtillus anthocyanosides in an internal medicine department. Therapeutique. 1972;48(9):579-581.
3. Bertuglia S, Malandrino S, Colantuoni A. Effect of Vaccinium myrtillus anthocyanosides on ischaemia reperfusion injury in hamster cheek pouch microcirculation. Pharmacol Res. 1995;31(3-4):183-187.
4. Bettini V. Effects of Vaccinium myrtillus anthocyanosides on vascular smooth muscle. Fitoterapia. 1984;55(5):265-272.
5. Bettini V, Mayellaro F, Ton P, Zogno M. Interactions between Vaccinium myrtillus anthocyanosides and serotonin on splenic artery smooth muscle. Fitoterapia. 1984;55(4):201-208.
6. Bever B. Plants with oral hypoglycemic action. Q J Crude Drugs Res. 1979;17:139-196.
7. Bomser J, Madhavi DL, Singletary K, Smith MA. In vitro anticancer activity of fruit extracts from Vaccinium species. PlantaMed. 1996;62(3):212-216.
8. Boniface R, Robert AM. Effect of anthocyanins on human connective tissue metabolism in the human. Klin Monatsbl Augenheilkd. 1996;209(6):368-372.
9. Bottecchia D. Preliminary report on the inhibitory effect of Vaccinium myrtillus antho-cyanosides on platelet aggregation and clot retraction. Fitoterapia. 1987;48:3-8.
10. Brantner A,. Grein E. Antibacterial activity of plant extracts used externally in traditional medicine. J Ethnopharmacol. 1994;44(l):35-40.
11. Bravetti GO, Fraboni E, Maccolini E. Preventive medical treatment of senile cataract with vitamin E and Vaccinium myrtillus anthocyanosides: clinical evaluation. Ann Ottalmol Clin Ocul. 1989;115:109-116.
12. Buliero G. The inhibitory effects of anthocyanosides on human platelet aggregation. Fitoterapia. 1989;60:69.
13. Canter PH., Ernst E. Anthocyanosides of Vaccinium myrtillus (bilberry) for night vision-a systematic review of placebo-controlled trials. Surv Ophthalmol. 2004;49(l):38-50.
14. Chatterjee A, Yasmin T, Bagchi D, Stohs SJ. Inhibition of Helicobacter pylori in vitro by various berry extracts, with enhanced susceptibility to clarithromycin. Mol Cell Biochem. 2004;265(l-2): 19-26.
15. Cignarella A, Nastasi M, Cavalli E, Puglisi L. Novel lipid-lowering properties of Vaccinium myrtillus L. leaves, a traditional antidiabetic treatment, in several models of rat dyslipidaemia: a comparison with ciprofibrate. Thromb Res. 1996;84(5):311-322.
16. Cluzel C, Bastide P, Wegman R, Tranche P. Enzymatic activities of retina and anthocyanoside extracts of Vaccinium myrtillus (lactate dehydrogenase, alpha-hydroxybutyrate dehydrogenase, 6-phosphogluconate dehydrogenase, glucose-6-phosphate dehydrogenase, alpha-glycerophosphate dehydrogenase, 5-nucleotidase, phosphoglucose isomerase). Biochem Pharmacol. 1970;19(7):2295-2302.
17. Coget J, Merlen JF. Clinical study of a new chemical agent for vascular protection, Difrarel 20, composed of anthocyanosides extracted from Vaccinum myrtillus. Phle-bologie. 1968;21(2):221-228.
18. Colantuoni A, Bertuglia S, Magistretti MJ, Donato L. Effects of Vaccinium myrtillus anthocyanosides on arterial vasomotion. Arzneimittelforschung. 1991;41(9):905-909.
19. Colombo D, Vescovini R. Controlled clinical trial of anthocyanosides from Vaccinium myrtillus in primary dysmenorrhea. G Ital Obstet Ginecol. 1985;7:1033-1038.
20. Cristoni A, Magistretti MJ. Antiulcer and healing activity of Vaccinium myrtillus anthocyanosides. Farmaco [Prat.] 1987;42(2):29-43.
21. Detre Z, Jellinek H, Miskulin M, Robert AM. Studies on vascular permeability in hypertension: action of anthocyanosides. Clin Physiol Biochem. 1986;4(2):143-149.
22. Erlund I, Marniemi J, Hakala P, Alfthan G, Meririnne E, Aro A. Consumption of black currants, lingonberries and bilberries increases serum quercetin concentrations. Eur J Clin Nutr. 2003;57(l):37-42.
23. Fdez M, Zaragoza F, Alvarez P. In vitro platelet aggregation effects of anthocyanosides of Vaccinium myrtilus L. Anales de la Real Academia de Farmacia. 1983;49:79-90.
24. Fiorini G, Biancacci A, Graziano FM. Perimetric and adaptometric modifications after ingestion of myrtillin associated with betacarotene. Ann Ottalmol Clin Ocul. 1965;91(6):371-386.
25. Fokina GI, Roikhel VM, Frolova MP, Frolova TV, Pogodina . The antiviral action of medicinal plant extracts in experimental tick-borne encephalitis. Vopr Virusol. 1993;38(4): 170-173.
26. Fuchikami H, Satoh H, Tsujimoto M, Ohdo S, Ohtani H, Sawada Y. Effects of herbal extracts on the function of human organic anion-transporting polypeptide OATP-B. Drug Metab Dispos. 2006;34(4):577-582.
27. Gabor M. Pharmacologic effects of flavonoids on blood vessels. Angiologica. 1972;9(3-6):355-374.
28. Gatta L. Experimental single-blind study: 60 pts with venous insufficiency received bilberry extract equivalent to 173 mg anthocyanins daily or placebo for 30 days. Fitoterapia. 1988;59(Suppl. 1):19.
29. Ghiringhelli C, Gregoratti L, Marastoni F. Capillarotropic action of anthocyanosides in high dosage in phlebopathic statis. Minerva Cardioangiol. 1978;26(4):255-276.
30. Grismondi GL. Treatment of phlebopathies caused by stasis in pregnancy. Minerva Ginecol. 1981;33(2-3):221-230.
31. Grosse-Ruyken FJ. The drug treatment of "myopia syndrome" (author's transl.). Klin Monatsbl Augenheilkd. 1977;171(4):623-627.
32. Havsteen B. Flavonoids, a class of natural products of high pharmacological potency. Biochem Pharmacol. 1983 ;32(7): 1141-1148.
33. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996;17(1):1-12.
34. Jayle GE, Aubert L. Action des glucosides d'anthocyanes sur la vision scotopique et mésopique du sujet normal. Therapie. 1964;19:171-185. Jayle GE, Aubry M, Gavini H, Braccini G, De la Baume C. Study concerning the action of anthocyanoside extracts of Vaccinium myrtillus on night vision. Ann Ocul (Paris). 1965;198(6):556-562.
35. Jonadet M, Meunier MT, Bastide J, Bastide P. Anthocyanosides extracted from Vitis vinifera, Vaccinium myrtillus and Pinus maritimus. I. Elastase-inhibiting activities in vitro. II. Compared angioprotective activities in vivo. J Pharm Belg. 1983;38(l):41-46.
36. Kadar A, Robert L, Miskulin M, Tixier JM, Brechemier D, Robert AM. Influence of anthocyanoside treatment on the cholesterol-induced atherosclerosis in the rabbit. Paroi Arterielle. 1979;5(4):187-205.
37. Katsube N, Iwashita K, Tsushida T, Yamaki K, Kobori M. Induction of apoptosis in cancer cells by Bilberry (Vaccinium myrtillus) and the anthocyanins. J Agric Food Chem. 2003;51(l):68-75.
38. Lagrue G, Robert AM, Miskulin M, Robert L, Pinaudeau Y, Hirbec G, Kamalodine T. Pathology of the microcirculation in diabetes and alterations of the biosynthesis of intercellular matrix macromolecules. Front Matrix Biol. 1979;7:324-335.
39. Laplaud PM, Lelubre A, Chapman MJ. Antioxidant action of Vaccinium myrtillus extract on human low density lipoproteins in vitro: initial observations. Fundam Clin Pharmacol. 1997;ll(l):35-40.
40. Leonardi M. Treatment of fibrocystic disease of the breast with myrtillus anthocyanins. Our experience. Minerva Ginecol. 1993;45(12):617-621.
41. Levy Y, Glovinsky Y. The effect of anthocyanosides on night vision. Eye. 1998;12(Pt 6):967-969.
42. Lietti A, Cristoni A, Picci M. Studies on Vaccinium myrtillus anthocyanosides. I. Vaso-protective and antiinflammatory activity. Arzneimittelforschung. 1976;26(5):829-832.
43. Lietti A, Forni G. Studies on Vaccinium myrtillus anthocyanosides. II. Aspects of anthocyanins pharmacokinetics in the rat. Arzneimittelforschung. 1976;26(5):832-835.
44. Lyons MM, Yu C, Toma RB, Cho SY, Reiboldt W, Lee J, van Breemen RB. Resveratrol in raw and baked blueberries and bilberries. J Agric Food Chem. 2003;51(20):5867-5870.
45. Magistretti MJ, Conti M, Cristoni A. Antiulcer activity of an anthocyanidin from Vaccinium myrtillus. Arzneimittelforschung. 1988;38(5):686-690.
46. Marcollet M, Bastide P, Tranche P. Effet angio-protecteur des anthocyanosides de Vaccinium myrtillus odjective vis a vis de la liberation de la lactate deshydrogenase (LDH) et de ses isoenzymes cardiaques chez le rat sounds a une epreuve de nage. CR Soc Biol. 1970;163:1786.
47. Martin-Aragon S, Basabe B, Benedi J, Villar AM. Antioxidant action of Vaccinium myrtillusL. Phytotherapy. 1998;46:S104-S106.
48. Martin-Aragon S, Basabe B, Benedi JM, Villar AM. In vitro and in vivo antioxidant properties of Vaccinium myrtillus. Pharm Biol. 1999;37(2): 109-113.
49. Mertz-Nielsen A, Munck LK, Bukhave K, Rask-Madsen J. A natural flavonoid, IdB 1027, increases gastric luminal release of prostaglandin E2 in healthy subjects. Ital J Gastroenterol. 1990;22(5):288-290.
50. Mian E. Anthocyanosides and microvessel walls: new findings on the mechanism of action of their protective effect in syndromes due to abnormal capillary fragility. Minerva Med. 1977;68(52):3565-3581.
51. Milbury PE, Graf B, Curran-Celentano JM, Blumberg JB. Bilberry (Vaccinium myrtillus) anthocyanins modulate heme oxygenase-1 and glutathione S-transferase-pi expression in ARPE-19 cells. Invest Ophthalmol Vis Sci. 2007;48(5):2343-2349.
52. Mitcheva M, Astroug H, Drenska D, Popov A, Kassarova M. Biochemical and morphological studies on the effects of anthocyans and vitamin E on carbon tetrachloride induced liver injury. Cell Microbiol. 1993;39(4):443-448.
53. Morazzoni P, Bombardelli E, Vaccinium myrtillus L. Fitoterapia. 1996;66:3-29. Morazzoni P, Livio S, Scilingo A, Malandrino S. Vaccinium myrtillus anthocyanosides pharmacokinetics in rats. Arzneimittelforschung. 1991;41(2):128-131.
54. Morazzoni P, Magistretti MJ. Effects of Vaccinium myrtillus anthocyanosides on prostacyclin-like activity in rat arterial issue. Fitoterapia. 1986;57:11-14.
55. Mosci C, Fioretto M, Polizzi A, De Marco R, Zingirian M. The influence of pro-cyanidolic anthocyanosides on macular recovery time and oscillatory potentials in the diabetic subject. Annli di Ottalmologi e Clinica Oculistica. 1988;114:473-479.
56. Muth ER, Laurent JM, Jasper P. The effect of bilberry nutritional supplementation on night visual acuity and contrast sensitivity. Altern Med Rev. 2000;5(2):164-173.
57. Neef H, Declercq P, Laekeman G. Hypoglycaemic activity of selected European plants. PhytotherRes. 1995;9:45-48.
58. Oliva E, Nicastro A, Sorcini A, Sarcinella R, La Torre F. Gli anticianosidi del mirtillo nel trattamento postoperatorio delle emorroidi. Aggior Med Chir. 1990;8(l):l-6.
59. Pautler EL, Maga JA, Tengerdy C. A pharmacologically potent natural product in the bovine retina. Exp Eye Res. 1986;42(3):285-288.
60. Perossini M., Guidi G, Chiellini S, Siravo D. Diabetic and hypertensive retinopathy therapy with Vaccinium myrtillus anthocyanosides (Tegens): double blind placebo controlled clinical trial. Annali di Ottalmaologia e Clinica Oculistica. 1987;113:1173-1190.
61. Pezzangora V, Barina R, de Stefani R, Rizzo M. La terapia medica con antocianosidi del mirtillo nei pazienti operati di emorroidectomia. Gazz Med Ital. 1984;143:405-409.
62. Politzer M. Experiences in the medical treatment of progressive myopia (author's transl.). Klin Monatsbl Augenheilkd. 1977;171(4):616-619.
63. Prior R, Cao G, Martin A, Sofic E, McEwen J, O'Brien C, et al. Antioxidant capacity as influenced by total phenolic and anthocyanin content, maturity, and variety of Vaccinium species. J Agric Food Chem. 1998;46:2686-2693.
64. Pulliero G, Montin S, Bettini V, Martino R, Mogno C, Lo Castro G. Ex vivo studyof the inhibitory effects of Vaccinium myrtillus anthocyanosides on human platelet aggregation. Fitoterapia. 1989;60:69-75.
65. Rasetti FRM, Caruso D, Galli G, Bosisio E. Extracts of Ginkgo biloba L. leaves and Vaccinium myrtillus L. fruits prevent photo induced oxidation of low density lipoprotein cholesterol. Phytomedicine. 1997;3:335-338.
66. Repossi P, Malagola R, De Cadilhac C. The role of anthocyanosides on vascular permeability in diabetic retinopathy. Ann Ottalmol Clin Ocul. 1987;113:357-361.
67. Rimando AM, Kalt W, Magee JB, Dewey J, Ballington JR. Resveratrol, pterostilbene, and piceatannolin vaccinium berries. J Agric Food Chem. 2004;52(15):4713-4719.
68. Scharrer A, Ober M. Anthocyanosides in the treatment of retinopathies (author's transl.). Klin Monatsbl Augenheilkd. 1981;178(5):386-389.
69. Spinella G. Natural anthocyanosides in treatment of peripheral venous insufficiency. Arch Med Intern. 1985;37:219.
70. Steigerwalt RD, Gianni B, Paolo M, Bombardelli E, Burki C, Schonlau F. Effects of mirtogenol on ocular blood flow and intraocular hypertension in asymptomatic subjects. Mol Vis. 2008;14:1288-1292.
71. Tori A, D'Errico F. Vaccinium myrtillus anthocyanosides in the treatment of stasis venous diseases of the lower limbs. Gazz Med Ital. 1980;139:217-224.
72. Varma SD, Mizuno A, Kinoshita JH. Diabetic cataracts and flavonoids. Science. 1977;195(4274):205-206.
73. Viana M, Barbas C, Bonet B, Bonet MV, Castro M, Fraile MV, Herrera E. In vitro effects of a flavonoid-rich extract on LDL oxidation. Atherosclerosis. 1996;123(1-2):83-91.
74. Wu QK, Koponen JM, Mykkanen HM, Torronen AR. Berry phenolic extracts modulate the expression of p21(WAFl) and Bax but not Bcl-2 in HT-29 colon cancer cells. J Agric Food Chem. 2007;55(4): 1156-1163.
75. Zadok D, Levy Y, Glovinskly Y. The effect of anthocyanosides on night vision tests. Invest Ophthalmol Vis Sci. 1997;38(4):S633.
76. Zadok D, Levy Y, Glovinsky Y. The effect of anthocyanosides in a multiple oral dose on night vision. Eye. 1999;13(Pt 6):734-736.
77. Zaragoza F, Iglesias I, Benedi J. Comparative study of the anti-aggregation effects of anthocyanosides and other agents. Arch Farmacol Toxicol. 1985;11(3):183-188.
78. Zhao C, Giusti MM, Malik M, Moyer MP, Magnuson BA. Effects of commercial anthocyanin-rich extracts on colonic cancer and nontumorigenic colonic cell growth. J Agric Food Chem. 2004;52(20):6122-6128.